gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CRDFHealthcareBiotechnology

Cardiff Oncology, Inc. Common Stock (CRDF)

$0.7602−12.51%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.76▼ 65.76% in range
Nov 4, 2025Low $0.76 · High $3.21Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Cardiff Oncology closed at $0.76 on Nov 5, down 12.51%, within 0.0% of its 52-week closing low. Volume of 570.8K shares was 1.43× its 20-day average (above normal).

Split-adjusted performance: -30.3% over one month, -52.5% over six months, -65.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $104K, down 14.0% from a year earlier, with a net margin of -8882.7%.

Short interest was 12.1M shares at the Oct 15 settlement (17.7% of float, 28.0 days to cover).

Market cap$59.1M77.8M shares
Revenue · quarter$104.0K−14.0% YoY
Diluted EPS$-0.14—
P/E · TTM—P/S 116.4×
Net margin-8,882.7%Gross 100.0%
Dividend yieldNone
52-week range0.76 – 3.21−76.3% from high
Volume570.8K1.43× 20-day avg
Volatility · 60d75.5%Annualised
Short % of float17.7%28.0 days to cover
Net cash$34.5MCash $34.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.6%1M −30.3%3M −23.4%6M −52.5%YTD −72.9%1Y −65.8%3Y −29.0%5Y −87.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum27
Revenue growth35
Net margin10
Value (low P/E)—
Size29

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →
Shares short12.1M+0.4% vs prior
Days to cover28.0Settled Oct 15
% of float17.7%
Short vol. 10d46.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CRDFCardiff Oncology$0.7602−12.51%−52.5%−14.0%−8882.7%—$59.1M
CGTXCognition Therapeutics$0.6405−6.26%−44.8%———$60.9MCompare
CSBRChampions Oncology$4.79−0.83%−20.0%+8.8%−2.8%—$66.7MCompare
INKTMiNK Therapeutics$10.10−4.70%−9.7%———$51.6MCompare
ELOXEloxx Pharmaceuticals$12.59−1.18%————$50.8MCompare
KLRSKalaris Therapeutics$2.10+3.96%−59.2%———$50.0MCompare
GRMLGreenland Mines$3.62−7.42%————$49.5MCompare
TILInstil Bio$6.97−0.29%−13.2%———$47.3MCompare
IMAImageneBio$4.08−0.49%−31.0%———$46.3MCompare

News about Cardiff Oncology

All news →
Cardiff Oncology to Participate in the UBS Global Biopharma ConferenceGlobeNewswire Inc. · 2d ago▲ PositiveCardiff Oncology to Participate in September 2026 ConferencesGlobeNewswire Inc. · Sep 2, 2026▲ PositiveCardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRCGlobeNewswire Inc. · May 21, 2026▲ PositiveCardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026GlobeNewswire Inc. · Apr 21, 2026▲ PositiveCardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual MeetingGlobeNewswire Inc. · Mar 19, 2026▲ Positive

Quick answers

What does Cardiff Oncology do?
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need.
What is CRDF's market cap?
$59.14M, based on the Nov 5 close of $0.76.
Does Cardiff Oncology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CRDF is sold short?
12.1M shares, 17.7% of float, as of Oct 15, 2026.
What sector is CRDF in?
Healthcare, in the Biotechnology industry.

About Cardiff Oncology

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

HQ: San Diego, CA31 employeesListed May 22, 1997cardiffoncology.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology